FrancophonIA/ELRC3.0 huggingface dataset:
English: - KEYTRUDA can cause harm or death to your unborn baby.
Danish: - Keytruda kan skade det ufødte barn eller øge risikoen for, at det dør.
English: Sixty-seven percent (67%) of patients had M1 disease and the majority had Stage IV disease (Stage IV 32%, Stage IVa 14%, Stage IVb 4%, and Stage IVc 44%).
Danish: 67% af patienterne havde M1-sygdom og størstedelen havde sygdom i stadie IV (stadie IV 32%, stadie IVa 14%, stadie IVb 4% og stadie IVc 44%).
English: Hazard ratio* (98% CI) p-Value (stratified log-rank) RFS at 6 months RFS rate RFS at 12 months RFS rate RFS at 18 months RFS rate
Danish: HR* (98% CI) p-værdi (stratificeret log-rank) RFS ved måned 6 RFS-rate RFS ved måned 12 RFS-rate RFS ved måned 18 RFS-rate
English: See Table 28 for p-Value for inferential test of PFS based on the pre-specified interim analysis, where statistical significance has been reached.
Danish: Se tabel 28 for p-værdien for inferentiel test af PFS baseret på den præspecificerede interimanalyse, hvor der er nået statistisk signifikans.
English: Table 4 summarises key efficacy measures at the final analysis in patients previously treated with ipilimumab, and the KaplanMeier curve for PFS is shown in Figure 3.
Danish: I tabel 4 opsummeres de centrale effektresultater efter den endelige analyse hos patienter, der tidligere har været behandlet med ipilimumab, og KaplanMeier-kurven for PFS er vist i figur 3.
English: Corticosteroids may also be given to you before receiving KEYTRUDA in combination with chemotherapy to prevent and/or treat nausea, vomiting, and other side effects caused by chemotherapy.
Danish: Du kan også få kortikosteroider, før du får Keytruda i kombination med kemoterapi for at forebygge og/eller behandle kvalme, opkastning og andre bivirkninger forårsaget af kemoterapi.
English: Rare myocarditis myocarditis k, pericarditis
Danish: Sjælden myokarditis myokarditis k, perikarditis
English: Uncommon sarcoidosis Not known solid organ transplant rejection
Danish: Ikke kendt afstødning af transplanterede solide organer
English: Incidences of Grades 3-5 adverse reactions were 76% for pembrolizumab combination therapy and 71% for sunitinib alone.
Danish: Forekomsten af bivirkninger af grad 3-5 var 76% for kombinationsbehandling med pembrolizumab og 71% for sunitinib alene.
English: • To avoid foaming, deliver the water along the walls of the vial and not directly on the lyophilised powder.
Danish: • Tilsæt vandet ned langs siden af hætteglasset og ikke direkte ned i det frysetørrede pulver for at undgå skumdannelse.
English: Hypothyroidism resolved in 153 (23.7%) patients, 10 with sequelae.
Danish: Hypotyroidisme gik over hos 153 (23,7%) patienter, 10 med sequelae.
English: L-histidine hydrochloride monohydrate Sucrose
Danish: L-histidin-hydrochloridmonohydrat Saccharose
English: There is no information on overdose with pembrolizumab.
Danish: Der findes ingen information vedrørende overdosering med pembrolizumab.
English: Fifteen percent of patients had disease progression following prior platinumcontaining neoadjuvant or adjuvant chemotherapy.
Danish: 15% af patienterne havde sygdomsprogression efter tidligere platinbaseret neoadjuvant eller adjuvant kemoterapi.
English: * Cetuximab, platinum, and 5-FU † Based on the stratified Cox proportional hazard model ‡ Response: Best objective response as confirmed complete response or partial response
Danish: * Cetuximab, platinbaseret behandling og 5-FU Baseret på den stratificerede Cox proportional hazard-model ‡ Respons: Bedste objektive respons, der er bekræftet komplet eller partielt respons
English: Based on the modelling and simulation of dose/exposure relationships for efficacy and safety for pembrolizumab, there are no clinically significant differences in efficacy or safety among the doses of 200 mg every 3 weeks, 2 mg/kg every 3 weeks, and 400 mg every 6 weeks as monotherapy (see section 4.2).
Danish: Baseret på modellering og simulering af forholdet mellem dosis og eksponering med hensyn til pembrolizumabs virkning og sikkerhed er der ingen klinisk signifikant forskel i virkning eller sikkerhed blandt doserne på 200 mg hver 3. uge, 2 mg/kg hver 3. uge og 400 mg hver 6. uge som monoterapi (se pkt.
English: Thyroid function and hormone levels should be monitored to ensure appropriate hormone replacement.
Danish: Thyroideafunktion og hormonniveauer skal monitoreres for at sikre passende hormonsubstitutionsbehandling.
English: Patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before receiving KEYTRUDA.
Danish: Patienter med EGFR- eller ALK-positive mutationer i tumor bør også have været i targeteret behandling inden behandling med KEYTRUDA.
English: The major efficacy outcome measures (ORR and CRR) were assessed by blinded independent central review according to the 2007 revised International Working Group (IWG) criteria.
Danish: De vigtigste resultatmål objektiv responsrate (ORR) og komplet remissionsrate (CRR) blev baseret på BICR (blinded independent central review)-vurdering i henhold til IWG (International Working Group)kriterierne revideret i 2007.
English: Pituitary function and hormone levels should be monitored to ensure appropriate hormone replacement.
Danish: Hypofysefunktion og hormonniveauer skal monitoreres for at sikre passende hormonsubstitutionsbehandling.
English: Sixteen percent (16%) had disease progression following platinum-containing neoadjuvant or adjuvant chemotherapy, and 84% had received 1-2 prior systemic regimens for metastatic disease.
Danish: 16% havde sygdomsprogression efter platinbaseret neoadjuverende eller adjuverende kemoterapi, og 84% havde tidligere fået 1-2 systemiske regimer for metastatisk sygdom.
English: The benefit of treatment with pembrolizumab versus the risk of possible organ rejection should be considered in these patients.
Danish: Fordelene ved behandling med pembrolizumab skal afvejes mod risikoen for mulig organafstødning hos disse patienter.
English: Patients should be monitored for changes in thyroid function (at the start of treatment, periodically during treatment and as indicated based on clinical evaluation) and clinical signs and symptoms of thyroid disorders.
Danish: Patienterne skal derfor monitoreres for ændringer i thyreoideafunktionen (ved behandlingsstart, periodevist i løbet af behandlingen og som indiceret på basis af den kliniske vurdering) samt for kliniske tegn og symptomer på thyreoideasygdomme.
English: Obligation to conduct post-authorisation measures
Danish: • Forpligtelse til at gennemføre foranstaltninger efter udstedelse af markedsføringstilladelse
English: Complications, including graft-versus-host-disease (GVHD), in people with bone marrow (stem cell) transplant that uses donor stem cells (allogeneic).
Danish: Komplikationer, inklusive graft versus host-sygdom (GVHD), hos personer der gennemgår knoglemarvstransplantation (stamcelletransplantation), hvor der anvendes stamceller fra en donor
English: People get KEYTRUDA after they have had surgery to remove melanoma to help prevent their cancer from coming back (adjuvant therapy).
Danish: Keytruda gives til patienter, når de har fået foretaget en operation for at fjerne modermærkekræft for at forebygge, at deres kræft vender tilbage (adjuverende behandling).
English: Additional biomarkers other than PD-L1 expression status by Immunohistochemistry (IHC) (e.g. PD-L2, RNA signature, etc.) predictive of pembrolizumab efficacy should be investigated together with more information regarding the pattern of expression of PD-L1 obtained in the ongoing NSCLC studies (P001, P010, P024 and P042) and urothelial carcinoma studies (KN045, KN052), HNSCC study (KN040) and resected Stage II melanoma adjuvant study (KN716):
Danish: Yderligere biomarkører, ud over PD-L1-ekspressionsstatus ved immunhistokemi (IHC) (f.eks. PD-L2, RNA-signatur osv.), der er prædiktive for pembrolizumabs virkning, skal undersøges sammen med yderligere information om mønstret for PD-L1-ekspression indhentet i igangværende NSCLC-studier (P001, P010, P024 og P042) og studier med urotelialt karcinom (KN045, KN052), HNSCC-studiet (KN040) og studiet med adjuverende behandling af resekteret stadie II-melanom (KN716):
English: Preparation and administration of the infusion
Danish: Klargøring og administration af infusionsvæske
English: Sixteen percent had stage IIIA; 46% had stage IIIB; 18% had stage IIIC (1-3 positive lymph nodes) and 20% had stage IIIC (≥ 4 positive lymph nodes); 50% were BRAF V600 mutation positive and 44% were BRAF wild-type.
Danish: 16% havde stadie IIIA; 46% havde stadie IIIB; 18% havde stadie IIIC (1-3 positive lymfeknuder), og 20% havde stadie IIIC (≥ 4 positive lymfeknuder); 50% var positive for BRAF V600-mutation og 44% var BRAF vildtype.
English: • If ALT or AST ≥ 3 times ULN but < 10 times ULN without concurrent total bilirubin ≥ 2 times ULN, both KEYTRUDA and axitinib should be withheld until these adverse reactions recover to Grades 0-1.
Danish: • Hvis ALAT eller ASAT er ≥ 3 gange ULN, men < 10 gange ULN uden samtidig total-bilirubinværdi ≥ 2 gange ULN, skal både KEYTRUDA og axitinib pauseres, indtil disse bivirkninger bedres til grad 0-1.
English: Number (%) of patients with event
Danish: Antal (%) patienter med hændelse
English: In case of liver metastasis with baseline Grade 2 elevation of AST or ALT, hepatitis with AST or ALT increases ≥ 50% and lasts ≥ 1 week
Danish: Levermetastaser med grad 2 forhøjelse af ASAT eller ALAT, hepatitis med ASAT- eller ALAT-stigning på ≥ 50% i forhold til baseline, og som varer ≥ 1 uge
English: Docetaxel 75 mg/m2 every 3 weeks
Danish: Docetaxel 75 mg/m2 hver 3. uge
English: 4 mL of concentrate in a 10 mL Type I clear glass vial, with a coated grey chlorobutyl stopper and an aluminium seal with a dark blue coloured flip-off cap, containing 100 mg pembrolizumab.
Danish: 4 ml koncentrat i et 10 ml klart hætteglas (type I-glas) med en coated grå chlorbutylprop og en aluminiumshætte med et mørkeblåt flip-off-låg, der indeholder 100 mg pembrolizumab.
English: Ninety percent of patients were treatment naïve, and 10% received prior adjuvant or neoadjuvant platinum-based chemotherapy.
Danish: 90% af patienterne var behandlingsnaive, og 10% havde tidligere fået adjuvant eller neoadjuvant platinbaseret kemoterapi.
English: - It is not known if KEYTRUDA passes into your breast milk.
Danish: - Det er ukendt, om Keytruda udskilles i mælken hos mennesker.
English: Investigations Very common blood creatinine increased alanine aminotransferase increased, aspartate aminotransferase increased, blood creatinine increased
Danish: Undersøgelser Meget almindelig forhøjet kreatinin i blodet forhøjet alaninaminotransferase, forhøjet aspartataminotransferase, forhøjet kreatinin i blodet
English: At the time of this analysis, the hazard ratio in the overall population (95% CI) was 0.59 (0.45, 0.78) with 84/432 (19.4%) events in the combination arm and 122/429 (28.4%) events in the sunitinib arm.
Danish: På tidspunktet for denne analyse var HR i den samlede population (95% CI): 0,59 (0,45; 0,78) med 84/432 (19,4%) hændelser i armen med kombinationsbehandling og 122/429 (28,4%) hændelser i sunitinib-armen.
English: No clinical data are available on the possible effects of pembrolizumab on fertility.
Danish: Der foreligger ingen data om pembrolizumabs mulige indvirkning på fertilitet.
English: Both pembrolizumab arms were superior to chemotherapy for PFS, and there was no difference between pembrolizumab doses.
Danish: Begge behandlingsarme med pembrolizumab havde bedre (superior) PFS i forhold til kemoterapi, og der var ingen forskel mellem pembrolizumab-doserne.
English: Table 2: Adverse reactions in patients treated with pembrolizumab*
Danish: Tabel 2: Bivirkninger hos patienter, som blev behandlet med pembrolizumab*
English: Patients receiving placebo plus chemotherapy who experienced independently-verified progression of disease were offered pembrolizumab as monotherapy.
Danish: Patienter, der fik placebo plus kemoterapi, som oplevede uafhængigt verificeret sygdomsprogression, blev tilbudt pembrolizumab som monoterapi.
English: The trial demonstrated a statistically significant improvement in RFS for patients randomised to the pembrolizumab arm compared with placebo at the pre-specified interim analysis.
Danish: Studiet viste en statistisk signifikant forbedring i RFS for patienter randomiseret til armen med pembrolizumab sammenlignet med placebo ved den præspecificerede interimanalyse.
English: An updated OS analysis was performed when patients had a median follow-up of 16.6 months (range: 0.1 to 26.3 months).
Danish: En opdateret OS-analyse blev udført, når patienterne havde en median opfølgingstid på 16,6 måneder (interval: 0,1 til 26,3 måneder).
English: Thyroid disorders, including hypothyroidism, hyperthyroidism and thyroiditis, have been reported in patients receiving pembrolizumab and can occur at any time during treatment.
Danish: Thyreoideasygdomme, herunder hypotyroidisme, hypertyroidisme og tyroiditis, er rapporteret hos patienter, der fik pembrolizumab, og kan forekomme i hele behandlingsforløbet.
English: KEYNOTE-054: Placebo-controlled trial for the adjuvant treatment of patients with completely resected melanoma
Danish: KEYNOTE-054: Placebokontrolleret studie med adjuverende behandling af patienter med komplet resekteret melanom
English: Reasons for cisplatin ineligibility included: baseline creatinine clearance of < 60 mL/min (50%), ECOG performance status of 2 (32%), ECOG performance status of 2 and baseline creatinine clearance of < 60 mL/min (9%), and other (Class III heart failure, Grade 2 or greater peripheral neuropathy, and Grade 2 or greater hearing loss; 9%).
Danish: Årsager til cisplatin-uegnethed var: creatininclearance på < 60 ml/min (50%) ved baseline, ECOG-performance-status på 2 (32%), ECOGperformance-status på 2 og creatinin-clearance på < 60 ml/min (9%) ved baseline og andre (hjertesvigt klasse III, perifer neuropati grad 2 eller højere og høretab grad 2 eller højere; 9%).
English: Eightyfive percent of patients had visceral metastases, including 21% with liver metastases.
Danish: 85% af patienterne havde viscerale metastaser, herunder 21% med levermetastaser.
English: BRAF mutation negative n=245
Danish: Negativ for BRAF-mutation n=245
English: Of the patients who recovered, 92 (84%) were rechallenged with either pembrolizumab (3%) or axitinib (31%) monotherapy or with both (50%).
Danish: 92 (84%) af de patienter, der bedredes, fik genoptaget behandlingen med enten pembrolizumab (3%) eller axitinib (31%) som monoterapi eller med begge (50%).
English: Patients underwent imaging every 12 weeks after the first dose of pembrolizumab for the first two years, then every 6 months from year 3 to 5, and then annually.
Danish: Patienterne fik foretaget billeddiagnostisk undersøgelse hver 12. uge efter den første dosis pembrolizumab i løbet af de første 2 år, herefter hver 6. måned fra år 3 til 5 og herefter årligt.
English: Corticosteroids can also be used as premedication, when pembrolizumab is used in combination with chemotherapy, as antiemetic prophylaxis and/or to alleviate chemotherapy-related adverse reactions.
Danish: Kortikosteroider kan også anvendes som præmedicinering, når pembrolizumab anvendes i kombination med kemoterapi, som profylaktisk antiemetisk behandling og/eller til at mildne kemoterapi-relaterede bivirkninger.
English: In patients with cHL (n=241) the incidence of hypothyroidism was 14.1% (all Grades) with 0.4% Grade 3.
Danish: Hos patienter med cHL (n=241) var forekomsten af hypotyroidisme 14,1% (alle grader) med 0,4% af grad 3.
English: In this patient population, the median observation time was 7.3 months (range: 1 day to 31 months) and the most frequent adverse reactions with pembrolizumab were fatigue (32%), nausea (20%), and diarrhoea (20%).
Danish: I denne patientpopulation var den mediane observationstid 7,3 måneder (interval: 1 dag til 31 måneder), og de hyppigste bivirkninger med pembrolizumab var: træthed (32%), kvalme (20%) og diarré (20%).
English: For severe infusion reactions, infusion should be stopped and pembrolizumab permanently discontinued (see section 4.2).
Danish: Ved alvorlige infusionsreaktioner skal infusionen stoppes og pembrolizumab seponeres permanent (se pkt.
English: Table 18: Efficacy results in KEYNOTE-087 and KEYNOTE-013
Danish: Tabel 18: Effektresultater i KEYNOTE-087 og KEYNOTE-013
English: Efficacy was evaluated for 276 patients from two defined cohorts, one which included patients previously treated with ipilimumab (and if BRAF V600 mutation-positive, with a BRAF or MEK inhibitor) and the other which included patients naïve to treatment with ipilimumab.
Danish: Virkningen blev vurderet hos 276 patienter fra to definerede kohorter, en kohorte, som inkluderede patienter, der tidligere har været behandlet med ipilimumab (og med en BRAF- eller MEK-hæmmer, hvis der forekom en BRAF V600-mutation), og den anden kohorte, som inkluderede patienter, der ikke tidligere har været behandlet med ipilimumab.
English: Table 19 summarises the key efficacy measures for the ITT population at the final analysis.
Danish: I tabel 19 opsummeres de centrale effektresultater for ITT-populationen ved den endelige analyse.
English: BRAF mutant without prior BRAF treatment
Danish: BRAF-mutation uden forudgående BRAFbehandling
English: Table 28 summarises key efficacy measures from the pre-specified interim analysis.
Danish: I tabel 28 opsummeres de vigtigste effektresultater fra den præspecificerede interimanalyse.
English: Vascular disorders Very common hypertension
Danish: Vaskulære sygdomme Meget almindelig hypertension
English: The median number of prior lines of therapy administered for the treatment of cHL was 5 (range 2 to 15).
Danish: Det mediane antal forudgående behandlingslinjer for cHL var 5 (2-15).
English: All prescribers of KEYTRUDA must be familiar with the Physician Information and Management Guidelines.
Danish: Alle læger, som påtænker at ordinere KEYTRUDA, skal sikre sig kendskab til indholdet i informationen til lægen og behandlingsvejledningen.
English: AstraZeneca Pharmaceuticals LP, Frederick Manufacturing Center (FMC) 633 Research Court
Danish: AstraZeneca Pharmaceuticals LP, Frederick Manufacturing Center (FMC) 633 Research Court Frederick, Maryland (MD) 21703 USA
English: In 20 subjects with ocular melanoma included in KEYNOTE-001, no objective responses were reported; stable disease was reported in 6 patients.
Danish: Hos 20 forsøgspersoner med okulært melanom, som var inkluderet i KEYNOTE-001, blev der ikke rapporteret objektivt respons.
English: • pembrolizumab 200 mg intravenously every 3 weeks in combination with axitinib 5 mg orally, twice daily.
Danish: • pembrolizumab 200 mg intravenøst hver 3. uge i kombination med axitinib 5 mg oralt, to gange dagligt.
English: Pembrolizumab Control
Danish: Pembrolizumab Kontrol
English: In patients with ALT ≥ 3 times ULN (Grades 2-4, n=116), ALT resolved to Grades 0-1 in 94%.
Danish: Hos patienter med ALAT ≥ 3 gange ULN (grad 2-4, n=116) forbedredes ALAT til grad 01 hos 94%.
English: Grades 2 or 3
Danish: Grad 2 eller 3
English: The baseline and prognostic disease characteristics of the study population of KEYNOTE-052 included a proportion of patients eligible for a carboplatin-based combination, for whom the benefit is being assessed in a comparative study, and patients eligible for mono-chemotherapy, for whom no randomised data are available.
Danish: Prognostiske sygdomskarakteristika ved baseline hos studiepopulationen i KEYNOTE-052 inkluderede en procentdel patienter, der var egnet til carboplatinbaseret kombinationsbehandling, hvor fordelen bliver vurderet i et komparativt studie, og patienter, der var egnede til mono-kemoterapi, hvor der ikke foreligger randomiserede data.
English: All patients received pembrolizumab for a median of 3 doses (range 1-35 doses), with 130 patients (84.4%) receiving pembrolizumab for 2 doses or more.
Danish: Alle patienter fik pembrolizumab med en median på 3 doser (interval: 1-35 doser), hvor 130 patienter (84,4%) fik 2 eller flere doser pembrolizumab.
English: Sixty-five percent of patients had M1c stage, 9% had a history of brain metastases, 66% had no and 34% had one prior therapy.
Danish: 65% af patienterne havde melanom i M1c-stadiet, 9% havde hjernemetastaser i anamnesen, 66% havde ikke tidligere fået behandling, og 34% havde forudgående fået ét behandlingsregime.
English: Eighty-seven percent of patients had visceral metastases, including 34% with liver metastases.
Danish: 87% af patienterne havde viscerale metastaser, herunder 34% med levermetastaser.
English: Table 5 summarises key efficacy measures in patients previously treated or naïve to treatment with ipilimumab, receiving pembrolizumab at a dose of 2 mg/kg based on a minimum follow-up time of 30 months for all patients.
Danish: I tabel 5 opsummeres de centrale effektresultater hos patienter, der tidligere har været eller ikke tidligere har været behandlet med ipilimumab, som fik pembrolizumab ved en dosis på 2 mg/kg baseret på en opfølgningstid på mindst 30 måneder for alle patienter.
English: Grade 3 or suspected StevensJohnson syndrome (SJS) or toxic epidermal necrolysis (TEN)
Danish: Grad 3 eller mistanke om StevensJohnsons syndrom (SJS) eller toksisk epidermal nekrolyse (TEN)
English: The efficacy of pembrolizumab was investigated in KEYNOTE-087 and KEYNOTE-013, two multicentre, open-label studies for the treatment of 241 patients with cHL.
Danish: Pembrolizumabs virkning blev undersøgt i KEYNOTE-087 og KEYNOTE-013, to åbne multicenterstudier hos 241 patienter med cHL.
English: If not used immediately, chemical and physical in-use stability of KEYTRUDA has been demonstrated for 96 hours at 2°C to 8°C.
Danish: Hvis Keytruda ikke anvendes straks, er der påvist kemisk og fysisk stabilitet i 96 timer ved 2 °C-8 °C.
English: • If ALT or AST ≥ 10 times ULN or > 3 times ULN with concurrent total bilirubin ≥ 2 times ULN, both KEYTRUDA and axitinib should be permanently discontinued and corticosteroid therapy may be considered.
Danish: • Hvis ALAT eller ASAT er ≥ 10 gange ULN eller > 3 gange ULN med samtidig total-bilirubinværdi ≥ 2 gange ULN, skal både KEYTRUDA og axitinib seponeres permanent, og behandling med kortikosteroider kan overvejes.
English: Grades 3 or 4
Danish: Grad 3 eller 4
English: Common pain in extremity, myositis w, arthritis myositis w, pain in extremity, arthritis myositis w, arthritis x,
Danish: Almindelig ekstremitetssmerter, myositis w, artritis myositis ekstremitetssmerter, artritis myositis w, artritis x,
English: The median number of prior lines of therapy administered for the treatment of cHL was 4 (range 1 to 12).
Danish: Det mediane antal forudgående behandlingslinjer for cHL var 4 (1-12).
English: Preliminary data from an early review showed a reduced survival with pembrolizumab monotherapy in patients whose tumours express PD-L1 with a CPS < 10 compared with standard chemotherapy.
Danish: Foreløbige data fra en tidlig gennemgang viste en nedsat overlevelse med pembrolizumab som monoterapi hos patienter, hvis tumorer udtrykker PD-L1 med CPS < 10 sammenlignet med standardkemoterapi.
English: When used in combination with pembrolizumab, dose escalation of axitinib above the initial 5 mg dose may be considered at intervals of six weeks or longer (see section 5.1).
Danish: Når axitinib anvendes i kombination med pembrolizumab kan øgning af axitinib-dosis til over initialdosis på 5 mg overvejes i intervaller på seks uger eller længere (se pkt.
English: Patients with BRAF V600E mutant melanoma were not required to have received prior BRAF inhibitor therapy.
Danish: Det var ikke et krav, at patienter med BRAF V600E-muteret melanom skulle have fået forudgående behandling med en BRAF-hæmmer.
English: The reconstituted vials and/or diluted intravenous bags may be stored for a cumulative time of up to 96 hours in a refrigerator (2°C - 8°C).
Danish: Rekonstituerede hætteglas og/eller fortyndede intravenøse infusionsposer kan opbevares sammenlagt op til 96 timer i køleskab (2 °C - 8 °C).